ABSTRACT Atrial natriuretic peptide is a peptide regulating salt and water balance, originally isolated from the cardiac atrium, where it is synthesised as part of a precursor molecule in specialised myocardial cells. The myocardium extends into the extrapulmonary part of the pulmonary veins in many species, including man. In some small mammals, however, such as the rat, mouse, and bat, it extends further to veins in the peripheral parts of the lung. Since this myocardial layer is continuous with that in the atrium, we have looked for the possible expression of the atrial natriuretic peptide gene in this tissue in rats. Strong immunoreactivity was seen for both the peptide and the N terminal sequence (cardiodilatin) of its precursor in extrapulmonary veins and in intrapulmonary veins extending into the lung as far as the second branching point, where it was localised in the dense cored granules by electron microscopy; in situ hybridisation showed atrial natriuretic peptide messenger RNA at identical sites. Chromatography and radioimmunoassay of extracts of extrapulmonary and intrapulmonary veins showed most of the atrial natriuretic peptide immunoreactivity to be in the uncleaved (precursor molecule) form. Thus the peptide is synthesised in veins both outside and inside the lung, and these extra-atrial sites may be an natriuretic peptide.
In man the myocardium extends outside the heart no further than the extrapulmonary veins. 7 In rodents, however, the cardiac muscle is known to extend beyond the atrium along pulmonary veins and into intrapulmonary veins. '8 In some species it is seen as far peripherally as the postcapillary venules, the so called "pulmonary myocardium."'9 Electron microscopy has shown these muscle cells to contain dense cored granules20 similar to those in the atrium. We have therefore investigated the possibility that atrial natriuretic peptide is produced by the myocardium in these blood vessels.
The A NP gene in the cardiac muscle ofrat extrapulmonary and intrapulmonary veins Methods
We used 26 male Wistar rats (mean (SD) weight 250 (5) g), previously allowed food and water ad libitum. Eleven were killed by overdose of sodium pentobarbitone (Euthatal, May and Baker) and the lungs and heart were dissected out intact. Of these, the left lung and ventricles were removed from the tissues of five animals and the right lungs with attached atria were processed for immunocytochemical study; from the other six the tissues were extracted for radioimmunoassay and chromatography. The remaining 15 rats were anaesthetised by intraperitoneal injection of sodium pentobarbitone and perfused transcardially either with Bouin's fluid for immunocytochemical study, with glutaraldehyde for electron microscopy or 4% paraformaldehyde solution for in situ hybridisation (five in each group).
IMMUNOCYTOCHEMISTRY
The right lung and atrium were fixed intact in Bouin's fluid for 16 hours, extensively washed in 30% alcohol, and processed to paraffin wax. Tissue was orientated in the wax blocks so that the atrium and extrapulmonary and intrapulmonary veins could all be seen in the same section. Sections (5 pm thick) were taken up on poly-L-lysine coated slides.2' Immunostaining was performed by the modified immunogold-silver staining (IGSS) technique.22 Sections were dewaxed and rehydrated, and then immersed in Lugol's iodine for five minutes, and in 2% aqueous sodium thiosulphate solution for 30 seconds. After being washed in buffer 1 (0 05 mol/l tris-HCI buffer pH 7 4, containing 2-5% NaCl and 0-5% Tween 80) slides were incubated with undiluted normal goat serum for 30 minutes, followed by appropriately diluted anti-atrial natriuretic peptide (anti-ANP) (dilution 1:4000) or anticardiodilatin (dilution 1:2000) serum for 90 minutes. The antisera were raised in rabbits against synthetic whole human ANP or cardiodilatin'-6; both cross react with the respective rat peptides (see also section of radioimmunoassay). After being washed in buffer 1 slides were rinsed in buffer 2 (0-5 mol/l tris-HCl, pH 8 2) . Goat anti-rabbit immunoglobulin adsorbed to 5 nm colloidal gold (GAR G5, Janssen Life Sciences), diluted 1:200 in buffer 2 containing 0-8% bovine serum albumin, was then applied for 60 minutes. Slides were washed in buffer 2 and then in distilled water, and the colloidal gold particles rendered visible for light microscopy by means of a silver intensification reagent (Intense II, Janssen Life Sciences). After counterstaining with haematoxylin or haematoxylin and eosin sections were dehydrated, cleared, and mounted in DPX (RA Lamb).
The controls for immunostaining and silver development were omission of primary antibody or immunogold reagent or both. The specificity of ANP and cardiodilatin antisera was assessed by preabsorption of diluted antiserum with ANP'-28 or cardiodilatin''6 respectively at a concentration of 10 nmol/ml.
PHOSPHOTUNGSTIC ACID HAEMATOXYLIN

STAINING
The sections of tissue fixed in Bouin's fluid and embedded in wax to be used for immunocytochemistry were stained by the phosphotungstic acid-haematoxylin method23 to show cardiac muscle.
ELECTRON MICROSCOPY
The respiratory tract and heart were removed intact from rats perfused transcardially with 2% glutaraldehyde solution in 01 mol/l phosphate buffer, pH7-2. Veins between the atrium and the hilum of the right lung (extrapulmonary) and the main branch of the vein within the lung (intrapulmonary) were dissected out. The atrial end ofthe extrapulmonary and the hilar end of the intrapulmonary veins were discarded and the tissues post-fixed in the same glutaraldehyde solution for two hours. After being washed for one hour in 0-1 mol/l phosphate buffer (pH 7 4) containing 0-1 mol/l sucrose, tissues were dehydrated in a graded series of ethanols, cleared in propylene oxide, and infiltrated with Araldite epoxy resin. Semithin (1 pm) sections from all blocks were taken up on glass slides and immunostained by the peroxidase-antiperoxidase method24 with the same anti-ANP (dilution 1:4000) or anti-cardiodilatin (dilution 1:2000) sera that were used for IGSS. Sections were screened to determine the best areas for electron microscopy and the corresponding blocks trimmed to remove unwanted areas. Ultrathin (70 nm) sections from these blocks were collected on nickel grids, etched for 10 minutes with 10% aqueous H202, and rinsed in distilled water. Sections were then incubated by floating the grids face down on drops of normal goat serum (diluted 1:30, 30 min), followed by incubation with the same anti-ANP or anti-cardiodilatin sera that were used for IGSS (dilution 1:600, 16 h) and goat anti-rabbit immunoglobulin antibody adsorbed to 20 nm gold colloidal particles (GAR G20, Janssen Life Sciences, diluted 1: 15, 1 h). After counterstaining in uranyl acetate and lead citrate, preparations were screened and photographed with a Zeiss IOCR electron microscope operating at 60 kv. Antiserum specificity was assessed by preabsorption with homologous antigen as for light microscopic immunocytochemistry. IN 
SITU HYBRIDISATION
A plasmid clone containing a cDNA fragment encoding the precursor of rat ANP25 was used as the source of cDNA for the preparation of a complementary RNA probe. The SP6 plasmid used for the synthesis of probes complementary to the coding sequence (cRNA probe) of rat ANP mRNA was constructed by inserting the Pst I fragment (620 nucleotides) of cDNA (prANP1O) into the polylinker region of pSP64. This recombinant plasmid, pSP-rANP-PP, was linearised with EcoRI,26 and labelled rat cRNA or mRNA transcripts of ANP-cDNA were synthesised as described previously.'4 The RNA probe was purified by extraction with phenol and chloroform and precipitated overnight in ethanol at -20°C. The total activity was about 1 1 x I07 cpm for probes labelled with phosphorus-32 and 2 5 x 107 cpm for probes labelled with sulphur-35.
Anaesthetised rats were perfused transcardially with 200 ml of ice cold PBS followed by 150 ml of 4% paraformaldehyde solution in 01l mol/l phosphate buffer (pH 7-4). The lungs and heart were removed intact and post-fixed in the same solution for four hours and then rinsed in PBS containing 15% sucrose overnight at 4C. Cryostat sections (20 gm) were mounted on slides coated with poly-L-lysine, dried overnight at 37°C, and then permeabilised with a 0-3% solution of Triton X-100 in PBS (15 min) followed by proteinase K solution27 and then 4% paraformaldehyde in PBS (5 min), and pre-hybridised in 50% formamide and 2X SSC for 15 minutes at 37°C. Hybridisation was carried out with 2-3 ng of cRNA probe (about 5 x lO cpm/section; 0-2-0 3 ng/pg), as described previously,'4 for 16-20 hours at 372-42TC. The preparations were dehydrated through graded alcohols containing 0-3 mol/l ammonium acetate, dried, and dipped in Ilford K-5 emulsion and exposed for 2-4 days at 4°C before development in a Kodak D-19 developer.
The specificity of in situ hybridisation was tested by hybridising separate sets of sections either with cRNA probe after treatment ofsections with RNAase or with non-complementary mRNA probes indentical to the coding strand of the mRNA of rat ANP.
RADIOIMMUNOASSAY AND CHROMATOGRAPHY
The lung and heart tissues were dissected rapidly. We then took samples of right atrium, extrapulmonary vein, intrapulmonary vein cleaned of adhering lung tissue, and peripheral lung consisting mostly of alveolar tissue. Tissues were extracted, immediately after dissection, by boiling them in 0 5 mol/l acetic acid (10% w/v) for 10 minutes and than stored at -20°C until assay or chromatography for ANP7 or cardiodilatin.28 Antisera were raised in rabbits immunised with a human ANP (Peninsula Laboratories), or with the asn'-lys'6 N terminal fragment of the prohormone (Peninsula Laboratories). The ANP antiserum showed 100% cross reactivity with rat ANP; the cross reactivity of the anti-cardiodilatin serum with the rat peptide is not known, but is presumed to be less than 100%. The cross reactivity with the whole proANP molecule is not known for either antiserum. The tracers were prepared by iodination of a human ANP or the asn'-lys"6 fragment by the chloramine T oxidation method with Na'25I (Amersham). The radioimmunoassays were set up in duplicate polystyrene tubes containing 0-06 mol/l sodium potassium phosphate buffer (with 0 3% w/v bovine serum albumin, 0 01 mol/l edetic acid and 0 05% w/v sodium azide). Ten microlitres of diluted (1:100 or 1:1000 in 0 5 mol/l acetic acid) tissue extracts were added to the sample tubes. Standard curves were constructed with synthetic a human ANP and with the asn'-lys'6 synthetic fragment. Ten microlitres of 0 5 mol/l acetic acid were added to all the standard tubes. After incubation at 4°C for four days the bound and free peptides were separated by adding 4 mg of charcoal and 400 jg of dextran per tube. After centrifugation at 800 g at 4°C, the supernatant (antibody bound peptide) was separated from the charcoal pellet (free peptide) and both were counted on a gamma counter. The assay detection limits, with 95% confidence, are 1 fmol/tube for ANP and 4 fmol/tube for cardiodilatin immunoreactivity. Assay coefficients of variation for ANP were 6% (intra-assay) and 9% (inter-assay), and correspondingly for cardiodilatin 9% and 12%,.
Tissue fractionation was carried out on a 0 9 cm x 90 cm gel column (Pharmacia) containing 60 ml of Sephadex G-l00. The column was eluted at a flow rate of 4-8 ml/h and 20 minute fractions (1 16 ml a fraction) were collected. An aliquot of each eluting fraction was assayed for ANP and for cardiodilatin immunoreactivity. Three separate chromatographic runs were undertaken for each tissue type. Alpha rat ANP and cardiodilatin asn'-arg67 (synthetic 67 amino acid N terminal fragment of the prohormone, Peninsula Laboratories) were chromatographed separately and their elution positions were determined.
Results
The presence of striated cardiac muscle within cardiac atrium and the wall of intrapulmonary and extrapulmonary veins, but not arteries, was demonstrated by clear blue staining with the phosphotungstic acid haematoxylin method, which is known to stain striated muscle29 (fig 1) . These areas of cardiac muscle showed strong immunoreactivity by immunogoldsilver staining with specific antisera for ANP and for cardiodilatin (fig 2) . The staining had a strong perinuclear pattern, characteristic of the pattern seen for ANP in atrial myocytes. scattered immunoreactive cells were seen, and none was detected beyond the second branching point, although a thin myocardial sheath was often seen. The immunostaining intensity and the frequency of immunoreactive cells was somewhat lower in the perfusion fixed specimens, particularly in the intrapulmonary vessels, where almost no immunoreactive cells were seen. Absorption tests of the antisera used showed that they were specific for their respective antigens.
Electron microscopic immunocytochemical study of ultrathin resin sections showed that immunoreactivity for both ANP and cardiodilatin was localised in dense cored granules (diameter 160-240 nm) in cardiac myocytes in extrapulmonary and intrapulmonary veins ( fig 3) ; the cells on the intimal side of the cardiac muscle sheath appeared to contain more secretory granules than those on the adventitial side. The striated nature of the muscle could be discerned easily by electron microscopy and was also clearly visible in thin resin sections by light microscopy.
Hybridisation of the radiolabelled cRNA probe to the mRNA encoding ANP precursor was revealed by the presence of silver grains in the autoradiograms. These deposits were seen over atrial myocytes and over the cardiac muscle in extrapulmonary and intrapulmonary veins (fig 4) . The position of the labelled cells corresponded to that of the cells showing cardiodilatin and ANP immunoreactivities. The strongest hybridisation labelling and greatest density of cells labelled with cRNA was seen in the atrium and extrapulmonary veins. Lower levels of labelling occurred in intrapulmonary veins and was present in scattered cells only. Labelling was not obtained in sections that had been pretreated with RNAase, or if non-complementary RNA probes were used.
The ANP and cardiodilatin concentrations measured by radioimmunoassay in atrial tissues and in extrapulmonary and intrapulmonary venous tissues are shown in the table. The highest concentrations were detected in the atrial tissues with decreasing concentrations in the extrapulmonary and the intrapulmonary veins and no detectable ANP or cardiodilatin immunoreactivity in peripheral lung (principally alveolar) tissue. The immunoreactivities were characterised by gel chromatographic fractionation of the tissue extracts ( fig 5) . A single peak that was eluted in the same fractions for both ANP and cardiodilatin contained most of the recovered immunoreactivity. A small amount of ANP immunoreactivity was eluted at the position of the synthetic a rat ANP, and some cardiodilatin immunoreactivity was detected between the elution points of the prohormone and the asn-'-arg67 N terminal fragment.
Discussion
Our findings demonstrate that myocardium in the extrapulmonary and intrapulmonary veins of the rat contains atrial natriuretic peptide and cardiodilatin immunoreactivity. Most of the myocytes in the extrapulmonary veins contained peptide immunoreactivity, but as the veins extended into the lung the proportion ofcells displaying atrial natriuretic peptide and cardiodilatin immunoreactivity declined. This was confirmed by immunocytochemistry, in situ hybridisation, and radioimmunoassay. Ultrastruc- The ANP gene in the cardiac muscle ofrat extrapulmonary and intrapulmonary veins metabolism of the peptide. When labelled with iodine-125 and injected into anaesthetised rats most of the peptide is taken up by the lungs,_4 and this uptake was found to be saturable in an in vitro rabbit lung preparation.35 In both cases the binding of radiolabelled ligand was prevented by pretreatment with excess unlabelled peptide, and it has been suggested that the removal of atrial natriuretic peptide by the lung may be an additional means of controlling the circulating levels of the peptide. 35 The mechanism causing release of atrial natriuretic peptide from pulmonary veins is uncertain. The peptide is released from the heart by atrial stretch36 and volume loading,37 38 and may also be released from dog pulmonary vein by stretching.39 Interestingly, in this study atrial natriuretic peptide and cardiodilatin immunoreactivities were less in the pulmonary veins of rats that were fixed by perfusion. The pressure of perfusion fluid could cause stretch of the vessels and thus release of the peptides. Release of atrial natriuretic peptide from atria of perfused isolated rat and rabbit hearts has been found when the perfusion fluid was made hypoxic, 40 and it has been shown in vivo in hypoxic rats.38 Atrial natriuretic peptide also causes constriction of coronary arteries4' and may act to reduce the pulmonary vasoconstriction that occurs in hypoxia.42 Thus atrial natriuretic peptide release from intrapulmonary veins may have a local paracrine effect in addition to contributing to the circulating concentrations of the peptide.
